68504-85-8

Upstream product

• 260975-13-1 5-(2-bromomethyl-[1,3]dioxolan-2-yl)-2-fluorobenzenesulfonamide 
• 210826-74-7 2-fluoro-5-(2-methyl-[1,3]dioxolan-2-yl)-benzenesulfonamide 
• 210826-84-9 2-(3-bromo-4-fluorophenyl)-2-methyl-[1,3]dioxolane 
• 1007-15-4 4-fluoro-3-bromoacetophenone 
• 2343-29-5 5-acetyl-2-fluorobenzenesulfonamide 

Downstream Products

• 260975-10-8 2-fluoro-5-oxiranyl-benzenesulfonamide 
• 68504-77-8 2-Fluoro-5-[1-hydroxyl-2-[[3-(3-fluorophenyl)-1-methylpropyl]amino]ethyl]benzenesulphonamide 
• 68504-54-1 2-Fluoro-5-[1-hydroxy-2-[[3-(4-fluorophenyl)-1-methylpropyl]-amino]ethyl]benzenesulphonamide 
• 68504-86-9 5-(2-Dibenzylamino-acetyl)-2-fluoro-benzenesulfonamide 

Relevant academic research and scientific papers

Synthesis of covalent [14C]-labeled diarylsulfonylurea (DASU) inhibitors of the processing and release of IL-1

CP-452,759 and CP-470,947, two covalent [14C]-labeled diarylsulfonylurea (DASU) inhibitors of the processing and release of IL-1 from human monocytes, have been synthesized. The radiosyntheses utilize [14C]-labeled phosgene to prepar

Phenylethanolamine therapeutic agents

Compounds of the general formula: STR1 and non-toxic physiologically acceptable salts thereof, in which R1 is a halogen atom or a group NR2 R3 ; R2 and R3, which may be the same or different, are hydrogen or (C1 -C6) straight or branched chain alkyl or R2 and R3 may, together with the nitrogen atom, form a 5 or 6 membered heterocyclic ring which may contain a further hetero atom selected from O, N or S; or R2 may be hydrogen and R3 may by group R4 CO or R4 SO2 where R4 is hydrogen or alkyl (C1-4); R5 is hydrogen or one or more halogen atoms or hydroxy or alkoxy (C1-4) groups; and X is CH2, O or a group NR6 where R6 is hydrogen or alkyl (C1-4). These compounds block β-adrenoreceptors.

Thiazolidine derivatives

The invention relates to thiazolidine derivatives having in 4-position a hydroxy group and a 3'-sulphamyl-phenyl substituent, in 2-position an imino group and in 1-position an aliphatic or cycloaliphatic substituent. Said thiazolidines have diuretic activity. The invention also relates to a process for the manufacture of said compounds.